The University of Chicago

Other

Arch Development Corporation

Ur Labs, Inc.

Salix Pharmaceuticals, Inc.

Jonathan Moss

Lorin K Johnson

Patrick A Singleton

Chun-Su Yuan

Joe G N Garcia

Michael F Roizen

Mark Lingen

William Drell

Joseph F Foss

Carl C Peck

Avery Tung

Joe GN Garcia

Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a &#x3bc;-opioid receptor antagonist.

Treatment with opioid antagonists and mTOR inhibitors

Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

Use of opioid antagonists

The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

Use of opioid antagonists to attenuate endothelial cell proliferation and migration

A method for preventing or treating opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.

Use of methylnaltrexone and related compounds

A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.

Use of methylnaltrexone and related compounds to treat chronic opioid use side affects

The present invention relates generally to the use of a combination of alkali metal hydroxides and alkaline-earth metal hydroxides as a scavenging material for cyanide gas. In particular, the present invention relates to a method and means for either filtering out cyanide gas or detoxifying areas contaminated with cyanide using Sodalime or Baralyme&trade;. The scavenging material of the invention is typically incorporated into a scrubbing device wherein a motor ( ) powers a fan ( ) to draw contaminated air into an inlet ( ) and across a filter ( ) which contains the scavenger material, thereby absorbing cyanide gas contained in the air.

Use of solid hydroxides as scavenging materials for cyanide gas

A method for preventing or treating the opioid induced side effect, inhibition of gastrointestinal motility is disclosed. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.

A method of detecting cyanide concentration in the cutaneously transpired gas of a patient, allowing for the timely implementation of an appropriate treatment. Where the skin of a patient suffering from cyanide poisoning has been burnt, the present invention provides for a noninvasive means of cyanide treatment. In practice, a material is impregnated with methemoglobin and attached to a patient's skin. A barrier means located between the impregnated material and the patient's skin allows for the transfer of cyanide gas from the patient into the material. However, this barrier means does not allow for the transfer of the methemoglobin from the impregnated material into the patient's skin. The material is monitored for photometric change, and, where a change indicative of cyanide poinsoning is present, appropriate treatment is administered.

Method for detecting cyanide in cutaneously transpired gas

A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.

Growing community of inventors

Chicago, IL, United States of America

Jonathan Moss